Inozyme Pharma, Inc. INZY · Stock Open Inozyme Pharma, Inc. in new tab
Inozyme Pharma, Inc. Analysis (INZY)
Is Inozyme Pharma, Inc. a good investment? Inozyme Pharma, Inc. (INZY) is currently trading at 4.00 USD.
Investor FAQ
Does Inozyme Pharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Inozyme Pharma, Inc.?
Inozyme Pharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Community Discussion